NEW YORK — Xylonix, an immuno-oncology biotech, and cancer diagnostics firm BioGemex announced today a memorandum of understanding to codevelop a predictive cancer immunotherapy treatment response diagnostic. 

The companies will jointly develop XDX-01, a pretreatment point-of-care diagnostic to predict a patient's reaction to T-cell mediated cancer immunotherapies in solid tumors.